Apogee Therapeutics, Inc. (APGE)
| Market Cap | 6.23B +165.1% |
| Revenue (ttm) | n/a |
| Net Income | -255.84M |
| EPS | -4.22 |
| Shares Out | 73.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 676,784 |
| Open | 82.69 |
| Previous Close | 84.24 |
| Day's Range | 81.68 - 84.90 |
| 52-Week Range | 26.20 - 85.94 |
| Beta | 1.02 |
| Analysts | Strong Buy |
| Price Target | 109.67 (+30.03%) |
| Earnings Date | May 11, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price target is $109.67, which is an increase of 30.03% from the latest price.
News
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone
Apogee Therapeutics, Inc. maintains a Strong Buy rating following positive 52-week maintenance data for zumilokibart in moderate-to-severe Atopic Dermatitis [AD]. APGE's half-life extended monoclonal ...
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript
Apogee Therapeutics: Two Shots A Year, One Shot At Disruption
Apogee Therapeutics (APGE) remains a Buy, supported by strong Phase 2 data for zumilokibart in atopic dermatitis (AD) and a robust cash position. Zumilokibart's infrequent dosing (Q3M/Q6M) offers a ke...
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
The data revealed that zumilokibart demonstrated durable maintenance of response with both 3- and 6-month dosing regimens, with 75% and 85% of patients maintaining EASI-75, respectively.
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients ma...
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for be...
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 1...
Apogee Therapeutics to Participate in Upcoming March Conferences
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46t...
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim E...
Apogee Therapeutics: 2026 Inflection Point In Immunology
Apogee Therapeutics (APGE) leverages IL-13 pathway optimization to enable less frequent dosing, targeting a leadership shift in biologic treatment for inflammatory diseases. APGE's $913 million cash p...
Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript
Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of...
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anti...
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potentia...
Apogee Therapeutics to Participate in Upcoming Conferences
SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences...
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million
SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Helen of Troy, Ferrari, Apogee Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday.
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for bes...
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for b...